It's the end of PC manufacturing business for HCL Infosystems

Homegrown PC maker HCL Infosystems, which competes with multinational giants like HP and Dell, will phase-off its manufacturing business in the next few years to improve margins and increase organisational efficiency.

hidden November 19, 2013 15:35:51 IST
It's the end of PC manufacturing business for HCL Infosystems

New Delhi: Homegrown PC maker HCL Infosystems, which competes with multinational giants like HP and Dell, will phase-off its manufacturing business in the next few years to improve margins and increase organisational efficiency.

The company will instead focus on strengthening the services and distribution verticals.

"We will be stopping manufacturing. My distribution today does lot of distribution of PCs of multiple brands... We will be in PC distribution and in after sales services but will not manufacture HCL branded products some time in the future," HCL Infosystems CEO and managing director Harsh Chitale told PTI.

Its the end of PC manufacturing business for HCL Infosystems

Reuters

On specific timeline, Chitale said the plan is underway but "manufacturing is not something that is keeping me awake, its not part of HCL story now".

The PC business accounts for about 8% (around Rs 1,000 crore) of HCL Infosystem's overall revenues and has been under pressure for some time now as new form factors like tablets and phablets are finding more takers.

In the last few years, most PC makers in the country have incurred losses due to the rupee's fluctuation against other currencies, especially the US dollar. This has hurt the PC business in India as it is low-margin and almost 90-95% of the components are imported.

The company has 15,000 full-time employees, of which manufacturing comprises less than 3%, Chitale added.

"Of this less than three per cent are in manufacturing, while some will immediately find opening in repair services, the remaining people who could lose their jobs would be less than the natural monthly attrition rate," he said.

The move is a part of the firm's restructuring efforts to focus on growth areas like services and distribution.

HCL Infosystems has transferred its solutions, services and learning business to wholly-owned subsidiaries --- HCL Infotech, HCL Services, and HCL Learning.

"The restructuring would help us focus on growth engines like distribution and services which are seeing double digit growth, while helping fix the bleeding parts," Chitale said.

This will also bring down conflicts within different business units of the company, he added.

Hindustan Computers Ltd (HCL) was formed in 1976. It was a top PC brand in the country before losing ground to foreign players like Hewlett-Packard and Dell.

The HCL Group is a $6.3 billion enterprise comprising two listed companies listed -- HCL Technologies and HCL Infosystems.

PTI

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

By welcoming Australia into Malabar exercise, India has shed inhibitions about Quad, going all out against China
India

By welcoming Australia into Malabar exercise, India has shed inhibitions about Quad, going all out against China

Just like then Australian prime minister Kein Rudd didn't want to antagonise China, and hence pulled out of the quad in 2008, India too had been treading carefully in matters involving the Chinese

US proposes not to issue temporary business visas for H-1B specialty occupations
World

US proposes not to issue temporary business visas for H-1B specialty occupations

The decision, made on the heels of 3-Nov presidential polls, is likely to impact several Indian companies, which send their technology professionals on B-1 visas for a short stay to complete jobs on-site in the US

After Johnson & Johnson, US pharma company Eli Lilly’s halts COVID-19 antibody treatment over safety concerns
World

After Johnson & Johnson, US pharma company Eli Lilly’s halts COVID-19 antibody treatment over safety concerns

Medical experts note that pauses in large clinical trials of coronavirus are not uncommon. They said its possible the bad reaction could be the result of an unrelated illness, and not the drug itself